Epidermal growth factor receptor pathway polymorphisms and the prognosis of hepatocellular carcinoma

American Journal of Cancer Research

Volumn 5, Issue 1, 2015, Pages 396-410

  Wang, Wenjia ^a,b   Ma, Xiao Pin ^a   Shi, Zhuqing ^a,b   Zhang, Pengyin ^a,b   Ding, Dong Lin ^a   Huang, Hui Xing ^a   Saiyin, Hexi Ge ^a   Chen, Tao Yang ^c   Lu, Pei Xin ^c   Wang, Neng Jin ^c   Yu, Hongjie ^a,b   Sun, Jielin ^d   Zheng, S Lilly ^d   Yu, Long ^a,b   Xu, Jianfeng ^a,b,e,f   Jiang, De Ke ^a,b,d  

^a FUDAN UNIVERSITY   (China)

^b FUDAN UNIVERSITY   (China)

^c QIDONG LIVER CANCER INSTITUTE   (China)

^d WAKE FOREST SCHOOL OF MEDICINE   (United States)

^e FUDAN UNIVERSITY   (China)

^f NORTHSHORE UNIVERSITY HEALTHSYSTEM   (United States)

Author keywords

EGF; EGFR; Genetic polymorphisms; Hepatocellular carcinoma; Survival; VEGF; VEGFR2

Indexed keywords

EPIDERMAL GROWTH FACTOR; EPIDERMAL GROWTH FACTOR RECEPTOR; VASCULOTROPIN; VASCULOTROPIN RECEPTOR 2;

ADULT; ARTICLE; CANCER PROGNOSIS; CONTROLLED STUDY; DISEASE FREE SURVIVAL; EPIDERMAL GROWTH FACTOR GENE; EPIDERMAL GROWTH FACTOR RECEPTOR GENE; EPIDERMAL GROWTH FACTOR RECEPTOR SIGNALING PATHWAY; FEMALE; GENOTYPE; HAPLOTYPE; HUMAN; LIVER CELL CARCINOMA; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; SIGNAL TRANSDUCTION; SINGLE NUCLEOTIDE POLYMORPHISM; SURVIVAL TIME; VASCULAR ENDOTHELIAL GROWTH FACTOR GENE; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR 2 GENE;

EID: 84964219491     PISSN: None     EISSN: 21566976     Source Type: Journal    
DOI: None     Document Type: Article

References (63)

1. Ferlay J, Shin HR, Bray F, Forman D, Mathers C and Parkin DM. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 2010; 127: 2893-2917.
2. Yang JD and Roberts LR. Hepatocellular carcinoma: A global view. Nat Rev Gastroenterol Hepatol 2010; 7: 448-458.
3. Zhao B, Lu J, Yin J, Liu H, Guo X, Yang Y, Ge N, Zhu Y, Zhang H and Xing J. A functional polymorphism in PER3 gene is associated with prognosis in hepatocellular carcinoma. Liver Int 2012; 32: 1451-1459.
4. Torzilli G, Belghiti J, Kokudo N, Takayama T, Capussotti L, Nuzzo G, Vauthey JN, Choti MA, De Santibanes E, Donadon M, Morenghi E and Makuuchi M. A snapshot of the effective indications and results of surgery for hepatocellular carcinoma in tertiary referral centers: is it adherent to the EASL/AASLD recommendations?: an observational study of the HCC East-West study group. Ann Surg 2013; 257: 929-937.
5. Takayasu K, Arii S, Ikai I, Omata M, Okita K, Ichida T, Matsuyama Y, Nakanuma Y, Kojiro M, Makuuchi M and Yamaoka Y. Prospective cohort study of transarterial chemoembolization for unresectable hepatocellular carcinoma in 8510 patients. Gastroenterology 2006; 131: 461-469.
6. De Luca A, Carotenuto A, Rachiglio A, Gallo M, Maiello MR, Aldinucci D, Pinto A and Normanno N. The role of the EGFR signaling in tumor microenvironment. J Cell Physiol 2008; 214: 559-567.
7. Stoscheck CM and King LE Jr. Role of epidermal growth factor in carcinogenesis. Cancer Res 1986; 46: 1030-1037.
8. Hansen TF, Sorensen FB, Spindler KL, Olsen DA, Andersen RF, Lindebjerg J, Brandslund I and Jakobsen A. Microvessel density and the association with single nucleotide polymorphisms of the vascular endothelial growth factor receptor 2 in patients with colorectal cancer. Virchows Arch 2010; 456: 251-260.
9. Kang D, Gridley G, Huang WY, Engel LS, Winn DM, Brown LM, Bravo-Otero E, Wu T, Diehl SR and Hayes RB. Microsatellite polymorphisms in the epidermal growth factor receptor (EGFR) gene and the transforming growth factor-alpha (TGFA) gene and risk of oral cancer in Puerto Rico. Pharmacogenet Genomics 2005; 15: 343-347.
10. Brandt B, Hermann S, Straif K, Tidow N, Buerger H and Chang-Claude J. Modification of breast cancer risk in young women by a polymorphic sequence in the egfr gene. Cancer Res 2004; 64: 7-12.
11. Choi JE, Park SH, Kim KM, Lee WK, Kam S, Cha SI, Kim CH, Kang YM, Kim YC, Han SB, Jung TH and Park JY. Polymorphisms in the epidermal growth factor receptor gene and the risk of primary lung cancer: a case-control study. BMC Cancer 2007; 7: 199.
12. Zhou Q, Cheung YB, Jada SR, Lim WT, Kuo WL, Gray JW, Lee AS and Chowbay B. EGFR Intron 1 polymorphism in Asian Populations and its correlation with EGFR gene expression and amplification in breast tumor tissues. Cancer Biol Ther 2006; 5: 1445-1449.
13. Zhang W, Stoehlmacher J, Park DJ, Yang D, Borchard E, Gil J, Tsao-Wei DD, Yun J, Gordon M, Press OA, Rhodes K, Groshen S and Lenz HJ. Gene polymorphisms of epidermal growth factor receptor and its downstream effector, interleukin-8, predict oxaliplatin efficacy in patients with advanced colorectal cancer. Clin Colorectal Cancer 2005; 5: 124-131.
14. Forsti A, Jin Q, Altieri A, Johansson R, Wagner K, Enquist K, Grzybowska E, Pamula J, Pekala W, Hallmans G, Lenner P and Hemminki K. Polymorphisms in the KDR and POSTN genes: association with breast cancer susceptibility and prognosis. Breast Cancer Res Treat 2007; 101: 83-93.
15. Ferrara N, Gerber HP and LeCouter J. The biology of VEGF and its receptors. Nat Med 2003; 9: 669-676.
16. Delongchamps NB, Peyromaure M and Dinh-Xuan AT. Role of vascular endothelial growth factor in prostate cancer. Urology 2006; 68: 244-248.
17. Gasparini G. Prognostic value of vascular endothelial growth factor in breast cancer. Oncologist 2000; 5 Suppl 1: 37-44.
18. Giatromanolaki A, Sivridis E and Koukourakis MI. Angiogenesis in colorectal cancer: prognostic and therapeutic implications. Am J Clin Oncol 2006; 29: 408-417.
19. Rudlowski C, Pickart AK, Fuhljahn C, Friepoertner T, Schlehe B, Biesterfeld S and Schroeder W. Prognostic significance of vascular endothelial growth factor expression in ovarian cancer patients: a long-term follow-up. Int J Gynecol Cancer 2006; 16 Suppl 1: 183-189.
20. Iavarone M, Lampertico P, Iannuzzi F, Manenti E, Donato MF, Arosio E, Bertolini F, Primignani M, Sangiovanni A and Colombo M. Increased expression of vascular endothelial growth factor in small hepatocellular carcinoma. J Viral Hepat 2007; 14: 133-139.
21. Park YN, Kim YB, Yang KM and Park C. Increased expression of vascular endothelial growth factor and angiogenesis in the early stage of multistep hepatocarcinogenesis. Arch Pathol Lab Med 2000; 124: 1061-1065.
22. Suzuki K, Hayashi N, Miyamoto Y, Yamamoto M, Ohkawa K, Ito Y, Sasaki Y, Yamaguchi Y, Nakase H, Noda K, Enomoto N, Arai K, Yamada Y, Yoshihara H, Tujimura T, Kawano K, Yoshikawa K and Kamada T. Expression of vascular permeability factor/vascular endothelial growth factor in human hepatocellular carcinoma. Cancer Res 1996; 56: 3004-3009.
23. Jinno K, Tanimizu M, Hyodo I, Nishikawa Y, Hosokawa Y, Doi T, Endo H, Yamashita T and Okada Y. Circulating vascular endothelial growth factor (VEGF) is a possible tumor marker for metastasis in human hepatocellular carcinoma. J Gastroenterol 1998; 33: 376-382.
24. Poon RT, Lau C, Pang R, Ng KK, Yuen J and Fan ST. High serum vascular endothelial growth factor levels predict poor prognosis after radiofrequency ablation of hepatocellular carcinoma: importance of tumor biomarker in ablative therapies. Ann Surg Oncol 2007; 14: 1835-1845.
25. Schneider BP, Radovich M and Miller KD. The role of vascular endothelial growth factor genetic variability in cancer. Clin Cancer Res 2009; 15: 5297-5302.
26. Giacalone A, Montalto G, Giannitrapani L, Balasus D, Terranova A, Cervello M, Soresi M and Marasa L. Association between single nucleotide polymorphisms in the cyclooxygenase-2, tumor necrosis factor-alpha, and vascular endothelial growth factor-A genes, and susceptibility to hepatocellular carcinoma. OMICS 2011; 15: 193-196.
27. Suenaga M, Yamada S, Fujii T, Fuchs BC, Okumura N, Kanda M, Kobayashi D, Tanaka C, Nakayama G, Sugimoto H, Koike M, Nomoto S, Fujiwara M, Takeda S, Hayashi K, Tanabe KK, Goto H and Kodera Y. A functional polymorphism in the epidermal growth factor gene predicts hepatocellular carcinoma risk in Japanese hepatitis C patients. Onco Targets Ther 2013; 6: 1805-1812.
28. Kong SY, Park JW, Lee JA, Park JE, Park KW, Hong EK and Kim CM. Association between vascular endothelial growth factor gene polymorphisms and survival in hepatocellular carcinoma patients. Hepatology 2007; 46: 446-455.
29. Wu LM, Xie HY, Zhou L, Yang Z, Zhang F and Zheng SS. A single nucleotide polymorphism in the vascular endothelial growth factor gene is associated with recurrence of hepatocellular carcinoma after transplantation. Arch Med Res 2009; 40: 565-570.
30. The International HapMap Project. Nature 2003; 426: 789-796.
31. Sherry ST, Ward M and Sirotkin K. dbSNP-database for single nucleotide polymorphisms and other classes of minor genetic variation. Genome Res 1999; 9: 677-679.
32. A haplotype map of the human genome. Nature 2005; 437: 1299-1320.
33. Stephens M and Donnelly P. A comparison of bayesian methods for haplotype reconstruction from population genotype data. Am J Hum Genet 2003; 73: 1162-1169.
34. Jin F, Xiong WJ, Jing JC, Feng Z, Qu LS and Shen XZ. Evaluation of the association studies of single nucleotide polymorphisms and hepatocellular carcinoma: a systematic review. J Cancer Res Clin Oncol 2011; 137: 1095-1104.
35. Nishida N and Kudo M. Recent advancements in comprehensive genetic analyses for human hepatocellular carcinoma. Oncology 2013; 84 Suppl 1: 93-97.
36. Ito Y, Takeda T, Sasaki Y, Sakon M, Yamada T, Ishiguro S, Imaoka S, Tsujimoto M, Higashiyama S, Monden M and Matsuura N. Expression and clinical significance of the erbB family in intrahepatic cholangiocellular carcinoma. Pat-hol Res Pract 2001; 197: 95-100.
37. Zhong JH, You XM, Gong WF, Ma L, Zhang Y, Mo QG, Wu LC, Xiao J and Li LQ. Epidermal growth factor gene polymorphism and risk of hepatocellular carcinoma: a meta-analysis. PLoS One 2012; 7: e32159.
38. Abu DBK, Yang M, Fuchs BC, Karl DL, Yamada S, Sninsky JJ, O'Brien TR, Dienstag JL, Tanabe KK and Chung RT. A functional polymorphism in the epidermal growth factor gene is associated with risk for hepatocellular carcinoma. Gastroenterology 2011; 141: 141-149.
39. Yang Z, Wu Q, Shi Y, Nie Y, Wu K and Fan D. Epidermal growth factor 61A > G polymorphism is associated with risk of hepatocellular carcinoma: a meta-analysis. Genet Test Mol Biomarkers 2012; 16: 1086-1091.
40. Yoshiya S, Fujimoto Y, Bekki Y, Konishi H, Yamashita Y, Ikegami T, Yoshizumi T, Shirabe K, Oda Y and Maehara Y. Impact of epidermal growth factor single-nucleotide polymorphism on recurrence of hepatocellular carcinoma after hepatectomy in patients with chronic hepatitis C virus infection. Cancer Sci 2014; 105: 646-650.
41. Komuves LG, Feren A, Jones AL and Fodor E. Expression of epidermal growth factor and its receptor in cirrhotic liver disease. J Histochem Cytochem 2000; 48: 821-830.
42. Morimitsu Y, Hsia CC, Kojiro M and Tabor E. Nodules of less-differentiated tumor within or adjacent to hepatocellular carcinoma: relative expression of transforming growth factor-alpha and its receptor in the different areas of tumor. Hum Pathol 1995; 26: 1126-1132.
43. Lin SY, Makino K, Xia W, Matin A, Wen Y, Kwong KY, Bourguignon L and Hung MC. Nuclear localization of EGF receptor and its potential new role as a transcription factor. Nat Cell Biol 2001; 3: 802-808.
44. Berasain C and Avila MA. The EGFR signalling system in the liver: from hepatoprotection to hepatocarcinogenesis. J Gastroenterol 2014; 49: 9-23.
45. Bassullu N, Turkmen I, Dayangac M, Yagiz Korkmaz P, Yasar R, Akyildiz M, Yaprak O, Tokat Y, Yuzer Y and Bulbul Dogusoy G. The Predictive and Prognostic Significance of c-erb-B2, EGFR, PTEN, mTOR, PI3K, p27, and ERCC1 Expression in Hepatocellular Carcinoma. Hepat Mon 2012; 12: e7492.
46. Berasain C, Nicou A, Garcia-Irigoyen O, Latasa MU, Urtasun R, Elizalde M, Salis F, Perugorria MJ, Prieto J, Recio JA, Corrales FJ and Avila MA. Epidermal growth factor receptor signaling in hepatocellular carcinoma: inflammatory activation and a new intracellular regulatory mechanism. Dig Dis 2012; 30: 524-531.
47. Hoshida Y, Villanueva A, Kobayashi M, Peix J, Chiang DY, Camargo A, Gupta S, Moore J, Wrobel MJ, Lerner J, Reich M, Chan JA, Glickman JN, Ikeda K, Hashimoto M, Watanabe G, Daidone MG, Roayaie S, Schwartz M, Thung S, Salvesen HB, Gabriel S, Mazzaferro V, Bruix J, Friedman SL, Kumada H, Llovet JM and Golub TR. Gene expression in fixed tissues and outcome in hepatocellular carcinoma. N Engl J Med 2008; 359: 1995-2004.
48. Hoshida Y, Villanueva A, Sangiovanni A, Sole M, Hur C, Andersson KL, Chung RT, Gould J, Kojima K, Gupta S, Taylor B, Crenshaw A, Gabriel S, Minguez B, Iavarone M, Friedman SL, Colombo M, Llovet JM and Golub TR. Prognostic gene expression signature for patients with hepatitis C-related early-stage cirrhosis. Gastroenterology 2013; 144: 1024-1030.
49. Aucejo F, Kim R, Zein N, Quintini C, Uso TD, Lopez R, Eghtesad B, Fung J, Miller C and Yerian L. Vascular endothelial growth factor receptor 2 expression in non-tumorous cirrhotic liver is higher when hepatoma is beyond Milan criteria. Liver Transpl 2009; 15: 169-176.
50. Huang J, Zhang X, Tang Q, Zhang F, Li Y, Feng Z and Zhu J. Prognostic significance and potential therapeutic target of VEGFR2 in hepatocellular carcinoma. J Clin Pathol 2011; 64: 343-348.
51. Patel SH, Kneuertz PJ, Delgado M, Kooby DA, Staley CA 3rd, El-Rayes BF, Kauh JS, Sarmiento JM, Hanish S, Cohen C, Farris AB 3rd and Maithel SK. Clinically relevant biomarkers to select patients for targeted inhibitor therapy after resection of hepatocellular carcinoma. Ann Surg Oncol 2011; 18: 3384-3390.
52. Zheng YB, Meng QW, Zhao W, Liu B, Huang JW, He X, Li Y, Hu BS and Lu LG. Prognostic value of serum vascular endothelial growth factor receptor 2 response in patients with hepatocellular carcinoma undergoing transarterial chemoembolization. Med Oncol 2014; 31: 843.
53. Meng QW, Li Y, Hu BS, Shao PJ, Zhan MX, Yu XY and Lu LG. [Prognostic significance of serum level of vascular endothelial growth factor receptor-2 in hepatocellular carcinoma patients after transcatheter arterial chemoembolization]. Zhonghua Yi Xue Za Zhi 2013; 93: 341-344.
54. Machado MV, Janeiro A, Miltenberger-Miltenyi G and Cortez-Pinto H. Genetic polymorphisms of proangiogenic factors seem to favor hepatocellular carcinoma development in alcoholic cirrhosis. Eur J Gastroenterol Hepatol 2014; 26: 438-443.
55. Maeng CH, Yi JH, Lee J, Hong JY, Choi MK, Jung HA, Park JO, Park SH, Park YS, Kang WK and Lim HY. Effects of single nucleotide polymorphisms on treatment outcomes and toxicity in patients treated with sunitinib. Anticancer Res 2013; 33: 4619-4626.
56. Scartozzi M, Faloppi L, Svegliati Baroni G, Loretelli C, Piscaglia F, Iavarone M, Toniutto P, Fava G, De Minicis S, Mandolesi A, Bianconi M, Giampieri R, Granito A, Facchetti F, Bitetto D, Marinelli S, Venerandi L, Vavassori S, Gemini S, D'Errico A, Colombo M, Bolondi L, Bearzi I, Benedetti A and Cascinu S. VEGF and VEGFR genotyping in the prediction of clinical outcome for HCC patients receiving sorafenib: the ALICE-1 study. Int J Cancer 2014; 135: 1247-1256.
57. Forner A, Llovet JM and Bruix J. Hepatocellular carcinoma. Lancet 2012; 379: 1245-1255.
58. Pore N, Jiang Z, Gupta A, Cerniglia G, Kao GD and Maity A. EGFR tyrosine kinase inhibitors decrease VEGF expression by both hypoxia-inducible factor (HIF)-1-independent and HIF-1-dependent mechanisms. Cancer Res 2006; 66: 3197-3204.
59. Inoue K, Torimura T, Nakamura T, Iwamoto H, Masuda H, Abe M, Hashimoto O, Koga H, Ueno T, Yano H and Sata M. Vandetanib, an inhibitor of VEGF receptor-2 and EGF receptor, suppresses tumor development and improves prognosis of liver cancer in mice. Clin Cancer Res 2012; 18: 3924-3933.
60. Lang SA, Brecht I, Moser C, Obed A, Batt D, Schlitt HJ, Geissler EK and Stoeltzing O. Dual inhibition of Raf and VEGFR2 reduces growth and vascularization of hepatocellular carcinoma in an experimental model. Langenbecks Arch Surg 2008; 393: 333-341.
61. Zhu AX, Duda DG, Sahani DV and Jain RK. Development of sunitinib in hepatocellular carcinoma: rationale, early clinical experience, and correlative studies. Cancer J 2009; 15: 263-268.
62. Yu W, Gu K, Yu Z, Yuan D, He M, Ma N, Lai S, Zhao J, Ren Z, Zhang X, Shao C and Jiang GL. Sorafenib potentiates irradiation effect in hepatocellular carcinoma in vitro and in vivo. Cancer Lett 2013; 329: 109-117.
63. Huynh H, Ong R and Soo KC. Foretinib demonstrates anti-tumor activity and improves overall survival in preclinical models of hepatocellular carcinoma. Angiogenesis 2012; 15: 59-70.